Viatris Announces Breyna™, the First FDA-Approved Generic Version of Symbicort®

The Asthma and Allergy Foundation of America (AAFA) is sharing this press release from Viatris Inc. to bring you the latest research news. [PRESS RELEASE] Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva Launch demonstrates companies’ commitment to bringing complex generic medicines to the…

Lesen Sie weiter auf: Viatris Announces Breyna™, the First FDA-Approved Generic Version of Symbicort®
Quelle: Asthma and Allergy Foundation of America
Titelbild/Grafik by Asthma and Allergy Foundation of America (AAFA)

Kommentare und Fragen

Möchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!

Weiteres von Asthma and Allergy Foundation of America

• September Research Update: Asthma, HES, CSU, and Universal Flu Vaccine
• AAFA’s Statement on FDA Decision on neffy®, Epinephrine Nasal Spray
• FDA Panel Finds Popular Decongestant Doesn’t Work and FDA May Remove It From the Market
• Asthma Peak Month: The Factors Behind the Asthma Peak in September
• 2023 Asthma Capitals™ Report: Where Does Your City Rank?
• Could Your Nasal Polyps Benefit from a Biologic Medicine? – Webinar
• August Research Update: Asthma, CSU, Epinephrine, Meat Allergy, Long COVID, and More
• A Parent’s Guide to Asthma Care at School (Video)
• Viatris Announces Launch of Breyna™, the First FDA-Approved Generic Version of Symbicort®
• Kimberly Spencer-McLeod: Turning Pain Into Purpose